LabCorp has launched a COVID-19 assay that assesses the ability of antibodies to inhibit the SARS-CoV-2 virus.

The company said its neutralizing antibody test, which uses patient plasma, will be available to biopharmaceutical companies, hospitals, blood banks and other places where plasma is screened.

Information gathered using the tests “could be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use,” the company said.